Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
protein degradation
Research
Amphista's targeted glue sticks the landing in early AML test
Amphista has reported preclinical leukemia data on its protein degrader, positioning the biotech to target a 2026 start date for a phase 1 trial.
Nick Paul Taylor
Dec 8, 2025 7:40am
Nurix trims staff as trial for lead BTK degrader kicks off
Nov 21, 2025 5:05am
AbbVie-partnered protein degrader specialist Plexium raises $60M
Aug 28, 2025 12:52pm
Plexium cuts staff, realigns resources to support pipeline
Jun 3, 2025 4:12pm
Sanofi pays $15M for another STAT6 degrader from Nurix collab
Jun 2, 2025 9:50am
Big Pharma-backed GlycoEra raises $130M for protein degraders
May 27, 2025 7:00am
